Nicholas W. Johnson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicholas W. Johnson has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Gavin Lawrence Woodhall
Institute of Health and Neurodevelopment, College of Health and Life Sciences, Aston University, Birmingham, UK
2 shared publications - Ian M. Stanford
Aston Brain Centre, Aston University, School of Life and Health Sciences, Birmingham, United Kingdom
2 shared publications - Mazhar Özkan
Department of Radiology, School of Medicine, Tekirdağ Namık Kemal University, Türkiye
2 shared publications - Adrian Philip Burgess
College of Health and Life Sciences, Aston University, Birmingham, UK
1 shared publication Emma J. Prokic
Aston Brain Centre, Aston University, School of Life and Health Sciences, Birmingham, B4 7ET, United Kingdom
1 shared publication- Francesca Spiga
Population Health Sciences, Bristol Medical School University of Bristol Bristol UK
1 shared publication
Latest Publications
- Open Access
- 21 July 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (7) , e0181633
Dopamine acting at D1-like, D2-like and α1-adrenergic receptors differentially modulates theta and gamma oscillatory activity in primary motor cortex
The loss of dopamine (DA) in Parkinson’s is accompanied by the emergence of exaggerated theta and beta frequency neuronal oscillatory activity in the primary motor cortex (M1) and basal ganglia. DA replacement therapy or deep brain stimulation reduces the power of these oscillations and this is coincident with an improvement in motor performance implying a causal relationship. Here we provide in vitro evidence for the differential modulation of theta and gamma activity in M1 by DA acting at receptors exhibiting conventional and non-conventional DA pharmacology. Recording local field potentials in deep layer V of rat M1, co-application of carbachol (CCh, 5 μM) and kainic acid (KA, 150 nM) elicited simultaneous oscillations at a frequency of 6.49 ± 0.18 Hz (theta, n = 84) and 34.97 ± 0.39 Hz (gamma, n = 84). Bath application of DA resulted in a decrease in gamma power with no change in theta power. However, application of either the D1-like receptor agonist SKF38393 or the D2-like agonist quinpirole increased the power of both theta and gamma suggesting that the DA-mediated inhibition of oscillatory power is by action at other sites other than classical DA receptors. Application of amphetamine, which promotes endogenous amine neurotransmitter release, or the adrenergic α1-selective agonist phenylephrine mimicked the action of DA and reduced gamma power, a result unaffected by prior co-application of D1 and D2 receptor antagonists SCH23390 and sulpiride. Finally, application of the α1-adrenergic receptor antagonist prazosin blocked the action of DA on gamma power suggestive of interaction between α1 and DA receptors. These results show that DA mediates complex actions acting at dopamine D1-like and D2-like receptors, α1 adrenergic receptors and possibly DA/α1 heteromultimeric receptors to differentially modulate theta and gamma activity in M1.
- 21 July 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (7) , e0181633
Open AccessDopamine acting at D1-like, D2-like and α1-adrenergic receptors differentially modulates theta and gamma oscillatory activity in primary motor cortex
The loss of dopamine (DA) in Parkinson’s is accompanied by the emergence of exaggerated theta and beta frequency neuronal oscillatory activity in the primary motor cortex (M1) and basal ganglia. DA replacement therapy or deep brain stimulation reduces the power of these oscillations and this is coincident with an improvement in motor performance implying a causal relationship. Here we provide in vitro evidence for the differential modulation of theta and gamma activity in M1 by DA acting at receptors exhibiting conventional and non-conventional DA pharmacology. Recording local field potentials in deep layer V of rat M1, co-application of carbachol (CCh, 5 μM) and kainic acid (KA, 150 nM) elicited simultaneous oscillations at a frequency of 6.49 ± 0.18 Hz (theta, n = 84) and 34.97 ± 0.39 Hz (gamma, n = 84). Bath application of DA resulted in a decrease in gamma power with no change in theta power. However, application of either the D1-like receptor agonist SKF38393 or the D2-like agonist quinpirole increased the power of both theta and gamma suggesting that the DA-mediated inhibition of oscillatory power is by action at other sites other than classical DA receptors. Application of amphetamine, which promotes endogenous amine neurotransmitter release, or the adrenergic α1-selective agonist phenylephrine mimicked the action of DA and reduced gamma power, a result unaffected by prior co-application of D1 and D2 receptor antagonists SCH23390 and sulpiride. Finally, application of the α1-adrenergic receptor antagonist prazosin blocked the action of DA on gamma power suggestive of interaction between α1 and DA receptors. These results show that DA mediates complex actions acting at dopamine D1-like and D2-like receptors, α1 adrenergic receptors and possibly DA/α1 heteromultimeric receptors to differentially modulate theta and gamma activity in M1.
- Open Access
- 1 June 2017
- Published by Elsevier in Neuropharmacology
- Vol. 119, 141-156
Phase-amplitude coupled persistent theta and gamma oscillations in rat primary motor cortex in vitro
- 1 June 2017
- Published by Elsevier in Neuropharmacology
- Vol. 119, 141-156
Open AccessPhase-amplitude coupled persistent theta and gamma oscillations in rat primary motor cortex in vitro
- 1 May 2013
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 371 (1-2) , 114-123
Constant light disrupts the circadian rhythm of steroidogenic proteins in the rat adrenal gland
- 1 May 2013
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 371 (1-2) , 114-123
Constant light disrupts the circadian rhythm of steroidogenic proteins in the rat adrenal gland